Dupilumab in Chinese adult participants with CRSwNP

Trial Identifier: EFC17026
Sponsor: Sanofi
Start Date: May 2023
Primary Completion Date: September 2024
Study Completion Date: November 2024
Condition: Nose and Sinus Disorder

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
CHINA Beijing, CHINA, 100730
CHINA Beijing, CHINA, 100044
CHINA Chengdu, CHINA, 610041
CHINA Chongqing, CHINA, 400016
CHINA Fuzhou, CHINA, 350005
CHINA Guangzhou, CHINA
CHINA Guangzhou, CHINA, 510163
CHINA Hangzhou, CHINA, 310003
CHINA Hefei, CHINA, 230001
CHINA Jinan, CHINA, 250102
CHINA Jingzhou, CHINA, 434020
CHINA Qingdao, CHINA
CHINA Shanghai, CHINA, 200065
CHINA Taiyuan, CHINA, 030001
CHINA Wuhan, CHINA, 430060
CHINA Wuhan, CHINA, 430022
CHINA Yantai, CHINA, 264000
CHINA Zibo, CHINA, 255036